Beaussant Y
Harvard Medical School (D.A.S., E.M., B.S.K., Y.B.), Boston, Massachusetts; Department of Psychosocial Oncology and Palliative Care (E.M., B.S.K., Y.B.), Dana-Farber Cancer Institute, Boston, Massachusetts.
ArticlePsilocybin
Safety and Efficacy of Psilocybin During Anticancer Treatment: A Phase II Trial Secondary Analysis.
ArticlePsilocybin
Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy.
ArticlePsychedelics
Feeling groovy? The present and future of psychedelic research in palliative care.
ArticlePsilocybin
Set and setting in psilocybin-assisted therapy: A qualitative study of patients with cancer and depression.
ArticleKetamine
Ketamine and Ketamine-Assisted Psychotherapy for Psychiatric and Existential Distress in Patients with Serious Medical Illness: A Narrative Review.
ArticlePsilocybin
Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.
ArticlePsychedelics
Older Adults in Psychedelic-Assisted Therapy Trials: A Systematic Review
ArticlePsilocybin
Older adults in psychedelic-assisted therapy trials: A systematic review.
ArticlePsilocybin
Applying Key Lessons from the Hospice and Palliative Care Movement to Inform Psychedelic-Assisted Therapy.
ArticlePsilocybin
Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.
ArticlePsilocybin
The Therapeutic Potential of Psychedelic-assisted Therapies for Symptom Control in Patients Diagnosed With Serious Illness: A Systematic Review.
ArticlePsychedelics
Psychedelic/entactogen‐assisted therapy for treatment of anxiety, depression and existential distress in adult palliative care
ArticlePsychedelics